- Moderna rejoined the Nasdaq-100 before the open on October 9, replacing Warner Bros. Discovery, which requires index-tracking funds to buy the stock.
- Shares closed up about 14% at $225 after closing at $197 the prior day, setting a fresh 52-week high.
- Intraday reports varied: Investing.com cited a 7.8% morning gain and Invezz cited a gain above 9% to $216.95 before trading at $208.69.
- The New York Times reported a public-private effort to speed cancer vaccine development, modeled on the COVID vaccine collaboration, with launch expected in December.
- Moderna and Merck are testing the individualized melanoma vaccine intismeran autogene, whose late-stage trial with Keytruda met its primary endpoint, with full data at ESMO in Madrid on October 24.
- Price targets sit well below the stock: Bank of America raised its target to $200 from $170 with a Neutral rating, and Koyfin's 12-month average target is $121.